Molecular Partners AG
NASDAQ:MOLNBiotechnology
+$0.03 today
- Market cap
- $100.28M
- Beta
- 0.71
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.55
Volume 0.00M
Average 0.00M
MOLN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Molecular Partners AGNASDAQ: MOLN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of CHF 936K fell 18.0% year over year, behind the -4.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.8% from the prior quarter. Over 3 fiscal years it compounded at -4.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -18.0% toward the trailing-twelve-month pace of -4.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
CHF · from the cash flow
- Latest · FY2025
- 4.42M CHF
- Year-over-year change
- +7.6%
- 4-year CAGR
- +2.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.42M | +7.6% |
| FY2024 | 2024-12-31 | 4.11M | -21.2% |
| FY2023 | 2023-12-31 | 5.21M | +2.3% |
| FY2022 | 2022-12-31 | 5.09M | +24.6% |
| FY2021 | 2021-12-31 | 4.09M | — |
Stock-Based Compensation vs competitors
How MOLN compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.1% is the 4th highest of 9, against a peer median of -13.8%.
- Over three fiscal years its annual growth of -4.6% compares with a peer median of -1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.22M USD | -43.4% | -16.7% | 115.2% | |
| LTM Mar 2026 | $10.03M USD | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $7.62M USD | -49.8% | -20.2% | — | |
| LTM Mar 2026 | $6.67M USD | -45.2% | -9.2% | 210.3% | |
| LTM Mar 2026 | $6.49M USD | -5.6% | +3.2% | — | |
| LTM Mar 2026 | $6.14M USD | +9.4% | -6.2% | 344.3% | |
| LTM Mar 2026 | $5.99M USD | +19.7% | +10.2% | 1140.6% | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M USD | +83.8% | +67.0% | — |
| Peer median (excluding MOLN) | — | -13.8% | -1.5% | 277.3% | |
Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.79M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Depreciation & Amortization | 2.57M | 2.39M | 2.42M | 2.37M | 2.14M |
| Deferred Income Tax | 2K | 0 | 0 | 2K | 2K |
| Stock-Based Compensation | 4.09M | 5.09M | 5.21M | 4.11M | 4.42M |
| Change in Working Capital | (34.67M) | (6.01M) | (6.01M) | (3.8M) | 1.16M |
| Accounts Receivables | (23.37M) | 25.26M | (933K) | (347K) | 463.2K |
| Inventory | 21.72M | (19.93M) | 0 | 0 | 0 |
| Accounts Payables | 1.66M | (5.34M) | (812K) | 524K | 62.08K |
| Other Working Capital | (34.67M) | (6.01M) | (4.27M) | (3.97M) | 630.33K |
| Other Non-Cash Items | 848K | (753K) | 1.36M | (7.88M) | 2.67M |
| Operating Cash Flow | (90.95M) | 118.57M | (59.01M) | (59.25M) | (51.26M) |
| Capital Expenditures | (1.31M) | (1.42M) | (575K) | (723K) | (714K) |
| Acquisitions (Net) | 374K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (88.88M) | (299.42M) | (277.83M) | (240.05M) | (66.28M) |
| Sales of Investments | 67.88M | 199.22M | 319.44M | 277.02M | 137.81M |
| Other Investing Activities | (304K) | 494K | 3.83M | 4.22M | 1.73M |
| Investing Cash Flow | (22.24M) | (101.12M) | 44.64M | 40.49M | 72.55M |
| Debt Repayment | (1.18M) | (1.19M) | (1.2M) | (1.21M) | (1.21M) |
| Common Stock Issued | 51.49M | 250K | 31K | 17.34M | 63K |
| Common Stock Repurchased | 0 | (631K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 267K | 250K | 31K | (1.7M) | 0 |
| Financing Cash Flow | 50.58M | (1.57M) | (1.17M) | 14.43M | (1.15M) |
| Effect of Forex Changes | 701K | 258K | (5.1M) | 894K | (1.36M) |
| Net Change in Cash | (61.91M) | 16.13M | (20.64M) | (3.44M) | 18.78M |
| Free Cash Flow | (92.26M) | 117.15M | (59.81M) | (59.97M) | (51.97M) |
Molecular Partners AG
NASDAQ:MOLN
Intrinsic Alpha fair value
Locked
Current Price
$2.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.